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ogy of this study included review of the relevant literature, assessing the possible 
implementation of the decision rules in the Hungarian context and an overview 
of the applications submitted to the Hungarian HTA office which fell into the third 
quadrant. Results: Three main decision rules of the cost-effectiveness can be 
used in the third quadrant. We came to the conclusion that using the same thresh-
old value requires no additional methodological analysis and it is a decision rule 
which is consistent in every case, but using the other two methods can be justified 
as well if the various stakeholders can reach an agreement on the methodological 
and ethical issues. ConClusions: In our conclusion we suggested using the same 
threshold value as in the first quadrant, although sometimes using the other two 
decision rules can also be justified.
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objeCtives: The objective of this research is to characterize the EUnetHTA [European 
Network for Health Technology Assessment] members based on their influence/
position in their respective national reimbursement process of pharmaceuticals/
other technologies and their responsibility to produce HTAs within their national 
setting. Methods: The organizations, in total counting 69, are rated according to 
their position and decision-making influence within the national reimbursement 
process. Categorizations will be: 1. responsible for the reimbursement decision; 2. 
adviser, scientific supplier in the reimbursement process; 3. not actively involved in 
the reimbursement process. In addition, the production of national HTAs – defined 
as an assessment of at least the relative effectiveness and safety of pharmaceuti-
cals/other technologies - will be explored and rated as: 1. production of HTAs; 2. no 
production of HTAs. Primary source for information gathering will be the websites 
of the EUnetHTA member organizations. Two independent researchers will extract 
the data, a member check will be conducted subsequent. Inclusion criteria for the 
information are: English language, not older than 2013, publicly available. If no infor-
mation is available on the respective websites, general overviews about countries 
are used for additional information research and validation. Results: Preliminary 
results: 1. 13 organizations (19%), 2. 21 organizations (30%), 3. 29 organizations (42%). 6 
organizations did not have available information on their homepage. Validation will be 
conducted through general overviews of the countries. Information regarding the HTA 
production of the 69 organizations is expected soon. ConClusions: The preliminary 
results present that around 50% of the EUnetHTA members are actively involved in 
the reimbursement process as responsible body for the decision-making or as adviser. 
Further research is needed to identify the influence of EUnetHTA members and their 
respective role in the national setting on EUnetHTA work.
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objeCtives: Launch of innovative therapies such as biologics adds substantial 
burden on national healthcare insurance systems. Rising costs of such innovative 
therapies led to the implementation of cost-containments measures, including 
denied or restricted reimbursement compared to licensed indications. Biosimilars’ 
introduction might decrease costs and increase access to biologics. The objective of 
this study was to assess the opportunity of indication extension with current and 
future biosimilars taking the example of the United Kingdom (UK). Methods: We 
conducted a review of licensed indications from European Medicines Agency and UK 
Medicine information website of biologics having biosimilars or best-selling biolog-
ics (around 1 USD billion of global sales per year) expected to have biosimilars in the 
five years to come. Scottish Medicine Consortium (SMC) and National Institute for 
Health and Care Excellence (NICE) review was performed for these drugs to iden-
tify potential restrictions in health technology assessment recommendations and 
rationale. Results: We identified 7 biologics having biosimilars and 15 best-selling 
biologics expected to have a biosimilar within the next 5 years. For the 22 selected 
biologics, we identified 110 licensed indications. Main therapeutic areas were immu-
nology/inflammation and oncology. SMC and NICE restricted or did not recommend 
indications for 94% and 80% of assessed biologics, respectively. Among these drugs, 
20% were recommended with a patient access scheme by NICE and 25% by SMC. 
Apart from the absence of dossier submission, the leading reason for restricted 
or denied recommendations was related to cost-effectiveness. ConClusions: By 
reducing drug acquisition cost, biosimilars are expected to improve incremental 
cost-effectiveness ratio of biologics and likely alleviate their restriction. Biosimilars 
represent a high potential societal value by contributing to pharmaceutical budget 
savings and by extending patient access in markets where originator was restricted 
for reimbursement to specific patient subgroups or not reimbursed at all.
HEaltH carE usE & PolicY studiEs – Patient registries & Post-Marketing 
studies
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to the assessment of medicines used at the end of life and for patients with rare 
conditions; introducing a new framework for assessing ultra-orphan medicines; 
and involving pharmaceutical company representatives in the discussion of their 
submission. Results: All SMC meetings have been held in public since May 2014 
with full capacity attendance and positive feedback. Private sessions to discuss 
commercial in confidence information have been kept to a minimum. Twenty end 
of life /orphan medicines have been assessed with input from the new Patient 
and Clinician Engagement (PACE) process since August 2014, with fifteen accepted 
for use and five not recommended. These include four medicines assessed using 
the ultra-orphan framework. Company representatives have been in attendance 
at meetings since November 2014 to help address outstanding questions from the 
Committee and clarify issues if required. ConClusions: SMC has worked closely 
with key stakeholders including clinicians, patient groups and the pharmaceuti-
cal industry to introduce these changes. Early experience suggests that these are 
meeting the desired objectives of increasing transparency, giving patient groups 
and clinicians a stronger voice in decision making and are leading to an increased 
acceptance rate for medicines used at the end of life and rare conditions.
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The first Early Dialogue (ED) between companies and a single HTA body in Europe 
took place in 2009. In addition to these ‘single-HTA’ advices, parallel regulatory and 
HTA advices have been organized at the EMA, with a limited number of HTA bodies, 
chosen by the company and each HTA body giving its own advice.objeCtives: In 
2012, the first pilots of multiple HTA ED took place in the frame of the European 
Network for HTA (EUnetHTA), coordinated by Haute Autorité de Santé (HAS). The 
objective was to have a collaborative approach to EDs, HTA bodies agreeing to 
exchange their views, identify the key issues of the development proposed by the 
company, discuss their positions and try to reach consensus advice as far as pos-
sible. Considering the success of this activity (10 EUnetHTA EDs done instead of 
3), the European Commission (DG SANTE) has published a call for tender for the 
conduct of 10 additional ‘multiple-HTA’ EDs and the production of a proposal for 
a permanent model for this activity in Europe. Methods: The SEED consortium, 
gathering 14 HTA bodies, coordinated by HAS, has been selected and has been 
operated since May 2014 (first ED) to October 2015 (final report). Results: 11 
EDs have been conducted (8 on drugs including 4 run in parallel with regulatory 
scientific advice at the EMA and 3 on medical devices). In addition to HTA bod-
ies and companies, patients representatives and health professionals have been 
involved in some EDS. A short survey has been conducted after each ED, allowing 
participants to propose improvements to the procedure, and provide input for 
the permanent model. ConClusions: The main outcomes of the 11 SEED EDs 
and the proposal for the permanent model will be presented for information and 
discussion with the audience.
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objeCtives: TEI, the Hungarian HTA office has been filling out an objective quality-
control checklist questionnaire regarding every submission. It critically evaluates 
them since November 2011. The checklist is based on the study of Inotai et al (2012) 
and allows the health-economic analyses in the submissions to be analysed with a 
standardized set of quality criteria. The goal of our poster was to analyze the data 
gathered from the filled checklists between the years 2011 and 2014, according 
to 14 different criteria, both cumulatively and annually, and exploring the pos-
sible correlations. Methods: During our analysis we gathered the answers to 
relevant questions using a VBA macro. We also checked the validity of the filled 
checklists, arranged the gathered data in a database and presented it on various 
graphs. Results: The total number of filled checklists at TEI was 220 between the 
years 2011 and 2014. The database of checklists allows us to analyze the proportion 
of submissions by two or more criteria, in order to find relevant correlations between 
them. Our results include that if the submission lacked a sensitivity analysis it was 
25 times more likely that the budget impact hadn’t been calculated either. The 
results also showed that the general quality of submissions improved according 
to most indicators during the timeframe in question, the only exception is that 
there are fewer submissions which include sensitivity analyses. ConClusions: 
The checklists allow us to conduct cumulative analyses on the submissions received 
by TEI, which helps to improve the quality of HTA analyses.
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objeCtives: Cost-effectiveness of health technologies is shown by their location 
relative to their comparators on the cost-effectiveness plane. The plain is divided 
into four quadrants by the axes. Methods determining the cost-effectiveness of 
therapies in the first quadrant has been thoroughly developed by the HTA meth-
odology. Cost-effectiveness of therapies in the second and fourth quadrant can be 
determined clearly. However in the third quadrant, where interventions are less 
costly but also less effective, there is a lack of a detailed decision rule regarding the 
cost-effectiveness of therapies. The aim of our poster was to investigate the possible 
decision-making rules which can be used in the third quadrant to assess the cost-
effectiveness. Furthermore we investigated the possible role of technologies in this 
quadrant in investment and disinvestment decisions. Methods: The methodol-
